logo
Log inSign Up. It's Free
  1. Home
  2. Syfovre®
  3. Interactions
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ActivationSamplesWeb AppsHub ServicesAI ProductsContact Sales
Tools & MorePrescribing InfoCoverageSavingsPrescriber AICompare Drugs
CompanyAboutInsightsCareersContact
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

Drugs interactions for Syfovre®

  • 219 Major drug interactions (including ingredients like Abatacept, Adalimumab, Adenovirus type 7 vaccine live)
  • 38 Moderate drug interactions (including ingredients like Anthrax immune globulin human, AstraZeneca COVID-19 Vaccine, Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated))
  • 6 Minor drug interactions (including ingredients like Allogeneic processed thymus tissue, Anthrax vaccine, Cladribine)
263 interactions for Syfovre®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Syfovre®.
Abatacept
The risk or severity of adverse effects can be increased when Abatacept is combined with Pegcetacoplan.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Pegcetacoplan.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pegcetacoplan.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pegcetacoplan.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pegcetacoplan.
Anakinra
The risk or severity of adverse effects can be increased when Anakinra is combined with Pegcetacoplan.
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Pegcetacoplan.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Pegcetacoplan.
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pegcetacoplan.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Pegcetacoplan.
Arsenic trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pegcetacoplan.
Avacincaptad pegol
The risk or severity of adverse effects can be increased when Avacincaptad pegol is combined with Pegcetacoplan.
Avacopan
The risk or severity of adverse effects can be increased when Avacopan is combined with Pegcetacoplan.
Azacitidine
The risk or severity of adverse effects can be increased when Azacitidine is combined with Pegcetacoplan.
Azathioprine
The risk or severity of adverse effects can be increased when Azathioprine is combined with Pegcetacoplan.
Bacillus calmette-guerin substrain tice live antigen
The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Pegcetacoplan.
Baricitinib
The risk or severity of adverse effects can be increased when Baricitinib is combined with Pegcetacoplan.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Pegcetacoplan.
Beclomethasone dipropionate
The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pegcetacoplan.
Belatacept
The risk or severity of adverse effects can be increased when Belatacept is combined with Pegcetacoplan.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Pegcetacoplan.
Belinostat
The risk or severity of adverse effects can be increased when Belinostat is combined with Pegcetacoplan.
Belumosudil
The risk or severity of adverse effects can be increased when Pegcetacoplan is combined with Belumosudil.
Bendamustine
The risk or severity of adverse effects can be increased when Bendamustine is combined with Pegcetacoplan.
Betamethasone
The risk or severity of adverse effects can be increased when Betamethasone is combined with Pegcetacoplan.
Bexarotene
The risk or severity of adverse effects can be increased when Bexarotene is combined with Pegcetacoplan.
Bimekizumab
The risk or severity of adverse effects can be increased when Bimekizumab is combined with Pegcetacoplan.
Bleomycin
The risk or severity of adverse effects can be increased when Bleomycin is combined with Pegcetacoplan.
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Pegcetacoplan.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Pegcetacoplan.
Bosutinib
The risk or severity of adverse effects can be increased when Bosutinib is combined with Pegcetacoplan.
Brentuximab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pegcetacoplan.
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Pegcetacoplan.
Budesonide
The risk or severity of adverse effects can be increased when Budesonide is combined with Pegcetacoplan.
Busulfan
The risk or severity of adverse effects can be increased when Busulfan is combined with Pegcetacoplan.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pegcetacoplan.
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Pegcetacoplan.
Capecitabine
The risk or severity of adverse effects can be increased when Capecitabine is combined with Pegcetacoplan.
Carbamazepine
The risk or severity of adverse effects can be increased when Carbamazepine is combined with Pegcetacoplan.
Carboplatin
The risk or severity of adverse effects can be increased when Carboplatin is combined with Pegcetacoplan.
Carfilzomib
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Pegcetacoplan.
Carmustine
The risk or severity of adverse effects can be increased when Carmustine is combined with Pegcetacoplan.
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Pegcetacoplan.
Chikungunya vaccine (live, attenuated)
The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Pegcetacoplan.
Chlorambucil
The risk or severity of adverse effects can be increased when Chlorambucil is combined with Pegcetacoplan.
Chloramphenicol
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Pegcetacoplan.
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Pegcetacoplan.
Cisplatin
The risk or severity of adverse effects can be increased when Cisplatin is combined with Pegcetacoplan.
Clobetasol propionate
The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pegcetacoplan.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Pegcetacoplan.
Corticotropin
The risk or severity of adverse effects can be increased when Corticotropin is combined with Pegcetacoplan.
Cortisone acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pegcetacoplan.
Crovalimab
The risk or severity of adverse effects can be increased when Crovalimab is combined with Pegcetacoplan.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Pegcetacoplan.
Cyclosporine
Pegcetacoplan may increase the immunosuppressive activities of Cyclosporine.
Cytarabine
The risk or severity of adverse effects can be increased when Cytarabine is combined with Pegcetacoplan.
Dacarbazine
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Pegcetacoplan.
Dactinomycin
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pegcetacoplan.
Danicopan
The risk or severity of adverse effects can be increased when Danicopan is combined with Pegcetacoplan.
Dasatinib
The risk or severity of adverse effects can be increased when Dasatinib is combined with Pegcetacoplan.
Daunorubicin
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pegcetacoplan.
Decitabine
The risk or severity of adverse effects can be increased when Decitabine is combined with Pegcetacoplan.
Deflazacort
The risk or severity of adverse effects can be increased when Deflazacort is combined with Pegcetacoplan.
Desoximetasone
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Pegcetacoplan.
Deucravacitinib
The risk or severity of adverse effects can be increased when Deucravacitinib is combined with Pegcetacoplan.
Dexamethasone
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Pegcetacoplan.
Dexrazoxane
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pegcetacoplan.
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Pegcetacoplan.
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Pegcetacoplan.
Diroximel fumarate
The risk or severity of adverse effects can be increased when Diroximel fumarate is combined with Pegcetacoplan.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pegcetacoplan.
Doxorubicin
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Pegcetacoplan.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Pegcetacoplan.
Efgartigimod alfa
The risk or severity of adverse effects can be increased when Efgartigimod alfa is combined with Pegcetacoplan.
Emapalumab
The risk or severity of adverse effects can be increased when Emapalumab is combined with Pegcetacoplan.
Epirubicin
The risk or severity of adverse effects can be increased when Epirubicin is combined with Pegcetacoplan.
Eribulin
The risk or severity of adverse effects can be increased when Eribulin is combined with Pegcetacoplan.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Pegcetacoplan.
Etoposide
The risk or severity of adverse effects can be increased when Etoposide is combined with Pegcetacoplan.
Everolimus
The risk or severity of adverse effects can be increased when Everolimus is combined with Pegcetacoplan.
Floxuridine
The risk or severity of adverse effects can be increased when Floxuridine is combined with Pegcetacoplan.
Flucytosine
The risk or severity of adverse effects can be increased when Flucytosine is combined with Pegcetacoplan.
Fludarabine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Pegcetacoplan.
Fludrocortisone
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pegcetacoplan.
Flunisolide
The risk or severity of adverse effects can be increased when Flunisolide is combined with Pegcetacoplan.
Fluocinolone acetonide
The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Pegcetacoplan.
Fluocinonide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Pegcetacoplan.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Pegcetacoplan.
Fluorouracil
The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pegcetacoplan.
Fluticasone furoate
The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pegcetacoplan.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pegcetacoplan.
Gemcitabine
The risk or severity of adverse effects can be increased when Gemcitabine is combined with Pegcetacoplan.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegcetacoplan.
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer is combined with Pegcetacoplan.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Pegcetacoplan.
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Pegcetacoplan.
Human adenovirus e serotype 4 strain cl-68578 antigen
The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Pegcetacoplan.
Hydrocortisone acetate
The risk or severity of adverse effects can be increased when Hydrocortisone acetate is combined with Pegcetacoplan.
Hydrocortisone butyrate
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Pegcetacoplan.
Hydrocortisone succinate
The risk or severity of adverse effects can be increased when Hydrocortisone succinate is combined with Pegcetacoplan.
Hydroxychloroquine
The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pegcetacoplan.
Hydroxyurea
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Pegcetacoplan.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pegcetacoplan.
Ibrutinib
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Pegcetacoplan.
Idarubicin
The risk or severity of adverse effects can be increased when Idarubicin is combined with Pegcetacoplan.
Idelalisib
The risk or severity of adverse effects can be increased when Idelalisib is combined with Pegcetacoplan.
Ifosfamide
The risk or severity of adverse effects can be increased when Ifosfamide is combined with Pegcetacoplan.
Imatinib
The risk or severity of adverse effects can be increased when Imatinib is combined with Pegcetacoplan.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Pegcetacoplan.
Infliximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Pegcetacoplan.
Interferon alfa-2b
The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pegcetacoplan.
Interferon alfa-n3
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pegcetacoplan.
Interferon beta-1b
The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pegcetacoplan.
Interferon gamma-1b
The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pegcetacoplan.
Iptacopan
The risk or severity of adverse effects can be increased when Iptacopan is combined with Pegcetacoplan.
Irinotecan
The risk or severity of adverse effects can be increased when Irinotecan is combined with Pegcetacoplan.
Ixabepilone
The risk or severity of adverse effects can be increased when Ixabepilone is combined with Pegcetacoplan.
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Pegcetacoplan.
Lenalidomide
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Pegcetacoplan.
Linezolid
The risk or severity of adverse effects can be increased when Linezolid is combined with Pegcetacoplan.
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Pegcetacoplan.
Mechlorethamine
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Pegcetacoplan.
Melphalan
The risk or severity of adverse effects can be increased when Melphalan is combined with Pegcetacoplan.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Pegcetacoplan.
Mercaptopurine
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Pegcetacoplan.
Methimazole
The risk or severity of adverse effects can be increased when Methimazole is combined with Pegcetacoplan.
Methotrexate
The risk or severity of adverse effects can be increased when Methotrexate is combined with Pegcetacoplan.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pegcetacoplan.
Mirikizumab
The risk or severity of adverse effects can be increased when Mirikizumab is combined with Pegcetacoplan.
Mitomycin
The risk or severity of adverse effects can be increased when Mitomycin is combined with Pegcetacoplan.
Mitoxantrone
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pegcetacoplan.
Mometasone furoate
The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Pegcetacoplan.
Monomethyl fumarate
The risk or severity of adverse effects can be increased when Monomethyl fumarate is combined with Pegcetacoplan.
Mosunetuzumab
The risk or severity of adverse effects can be increased when Mosunetuzumab is combined with Pegcetacoplan.
Mycophenolate mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pegcetacoplan.
Mycophenolic acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pegcetacoplan.
Natalizumab
The risk or severity of immunosuppression can be increased when Pegcetacoplan is combined with Natalizumab.
Nelarabine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Pegcetacoplan.
Nilotinib
The risk or severity of adverse effects can be increased when Nilotinib is combined with Pegcetacoplan.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pegcetacoplan.
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Pegcetacoplan.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pegcetacoplan.
Olaparib
The risk or severity of adverse effects can be increased when Olaparib is combined with Pegcetacoplan.
Oxaliplatin
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pegcetacoplan.
Ozanimod
The risk or severity of adverse effects can be increased when Ozanimod is combined with Pegcetacoplan.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pegcetacoplan.
Palbociclib
The risk or severity of adverse effects can be increased when Palbociclib is combined with Pegcetacoplan.
Panobinostat
The risk or severity of adverse effects can be increased when Panobinostat is combined with Pegcetacoplan.
Pazopanib
The risk or severity of adverse effects can be increased when Pazopanib is combined with Pegcetacoplan.
Pegaspargase
The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pegcetacoplan.
Peginterferon alfa-2a
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pegcetacoplan.
Peginterferon alfa-2b
The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pegcetacoplan.
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Pegcetacoplan.
Pemetrexed
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Pegcetacoplan.
Penicillamine
The risk or severity of adverse effects can be increased when Penicillamine is combined with Pegcetacoplan.
Pentostatin
The risk or severity of adverse effects can be increased when Pentostatin is combined with Pegcetacoplan.
Phenylalanine
The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pegcetacoplan.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegcetacoplan.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Pegcetacoplan.
Pirtobrutinib
The risk or severity of adverse effects can be increased when Pegcetacoplan is combined with Pirtobrutinib.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Pegcetacoplan.
Ponatinib
The risk or severity of adverse effects can be increased when Ponatinib is combined with Pegcetacoplan.
Ponesimod
The risk or severity of adverse effects can be increased when Ponesimod is combined with Pegcetacoplan.
Pozelimab
The risk or severity of adverse effects can be increased when Pozelimab is combined with Pegcetacoplan.
Pralatrexate
The risk or severity of adverse effects can be increased when Pralatrexate is combined with Pegcetacoplan.
Prednisolone
The risk or severity of adverse effects can be increased when Prednisolone is combined with Pegcetacoplan.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Pegcetacoplan.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Pegcetacoplan.
Propylthiouracil
The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pegcetacoplan.
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Pegcetacoplan.
Rilonacept
The risk or severity of adverse effects can be increased when Rilonacept is combined with Pegcetacoplan.
Risankizumab
The risk or severity of adverse effects can be increased when Risankizumab is combined with Pegcetacoplan.
Ritlecitinib
The risk or severity of adverse effects can be increased when Ritlecitinib is combined with Pegcetacoplan.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Pegcetacoplan.
Ropeginterferon alfa-2b
The risk or severity of adverse effects can be increased when Ropeginterferon alfa-2b is combined with Pegcetacoplan.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Pegcetacoplan.
Rubella virus vaccine
The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pegcetacoplan.
Ruxolitinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pegcetacoplan.
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Pegcetacoplan.
Satralizumab
The risk or severity of adverse effects can be increased when Satralizumab is combined with Pegcetacoplan.
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Pegcetacoplan.
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Pegcetacoplan.
Siponimod
The risk or severity of adverse effects can be increased when Siponimod is combined with Pegcetacoplan.
Sirolimus
The risk or severity of adverse effects can be increased when Sirolimus is combined with Pegcetacoplan.
Smallpox (Vaccinia) Vaccine, Live
The risk or severity of infection can be increased when Smallpox (Vaccinia) Vaccine, Live is combined with Pegcetacoplan.
Sorafenib
The risk or severity of adverse effects can be increased when Sorafenib is combined with Pegcetacoplan.
Spesolimab
The risk or severity of adverse effects can be increased when Spesolimab is combined with Pegcetacoplan.
Streptozocin
The risk or severity of adverse effects can be increased when Streptozocin is combined with Pegcetacoplan.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pegcetacoplan.
Sunitinib
The risk or severity of adverse effects can be increased when Sunitinib is combined with Pegcetacoplan.
Sutimlimab
The risk or severity of adverse effects can be increased when Sutimlimab is combined with Pegcetacoplan.
Temozolomide
The risk or severity of adverse effects can be increased when Temozolomide is combined with Pegcetacoplan.
Temsirolimus
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Pegcetacoplan.
Teniposide
The risk or severity of adverse effects can be increased when Teniposide is combined with Pegcetacoplan.
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pegcetacoplan.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Pegcetacoplan.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Pegcetacoplan.
Thiotepa
The risk or severity of adverse effects can be increased when Thiotepa is combined with Pegcetacoplan.
Tioguanine
The risk or severity of adverse effects can be increased when Tioguanine is combined with Pegcetacoplan.
Tixocortol
The risk or severity of adverse effects can be increased when Tixocortol is combined with Pegcetacoplan.
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Pegcetacoplan.
Topotecan
The risk or severity of adverse effects can be increased when Topotecan is combined with Pegcetacoplan.
Trabectedin
The risk or severity of adverse effects can be increased when Trabectedin is combined with Pegcetacoplan.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Pegcetacoplan.
Triamcinolone
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Pegcetacoplan.
Trifluridine
The risk or severity of adverse effects can be increased when Trifluridine is combined with Pegcetacoplan.
Typhoid Vaccine Live
The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Pegcetacoplan.
Upadacitinib
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Pegcetacoplan.
Varicella zoster vaccine (live/attenuated)
The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Pegcetacoplan.
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Pegcetacoplan.
Vilanterol
The risk or severity of adverse effects can be increased when Vilanterol is combined with Pegcetacoplan.
Vinblastine
The risk or severity of adverse effects can be increased when Vinblastine is combined with Pegcetacoplan.
Vincristine
The risk or severity of adverse effects can be increased when Vincristine is combined with Pegcetacoplan.
Vinorelbine
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Pegcetacoplan.
Voclosporin
The risk or severity of adverse effects can be increased when Voclosporin is combined with Pegcetacoplan.
Vorinostat
The risk or severity of adverse effects can be increased when Vorinostat is combined with Pegcetacoplan.
Yellow fever vaccine
The risk or severity of infection can be increased when Yellow fever vaccine is combined with Pegcetacoplan.
Zidovudine
The risk or severity of adverse effects can be increased when Zidovudine is combined with Pegcetacoplan.
Zilucoplan
The risk or severity of adverse effects can be increased when Zilucoplan is combined with Pegcetacoplan.
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pegcetacoplan.
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Pegcetacoplan.
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Pegcetacoplan.
Clostridium tetani toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegcetacoplan.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegcetacoplan.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Pegcetacoplan.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Pegcetacoplan.
Elasomeran
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Pegcetacoplan.
Etrasimod
The risk or severity of immunosuppression can be increased when Pegcetacoplan is combined with Etrasimod.
Fingolimod
Pegcetacoplan may increase the immunosuppressive activities of Fingolimod.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pegcetacoplan.
Hepatitis A Vaccine
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pegcetacoplan.
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pegcetacoplan.
Janssen COVID-19 Vaccine
The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Pegcetacoplan.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Pegcetacoplan.
Leflunomide
The risk or severity of adverse effects can be increased when Pegcetacoplan is combined with Leflunomide.
Lopinavir
The serum concentration of Pegcetacoplan can be increased when it is combined with Lopinavir.
Magnesium
The serum concentration of Magnesium can be decreased when it is combined with Pegcetacoplan.
Measles virus vaccine live attenuated
The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Pegcetacoplan.
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Pegcetacoplan.
mRNA-1345
The therapeutic efficacy of mRNA-1345 can be decreased when used in combination with Pegcetacoplan.
Mumps virus strain B level jeryl lynn live antigen
The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Pegcetacoplan.
Nuvaxovid
The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Pegcetacoplan.
Rabies immune globulin, human
The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Pegcetacoplan.
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pegcetacoplan.
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Pegcetacoplan.
Respiratory syncytial virus vaccine, adjuvanted
The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Pegcetacoplan.
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Pegcetacoplan.
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegcetacoplan.
Sulfamethoxazole
The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pegcetacoplan.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Pegcetacoplan.
Tick-borne encephalitis vaccine (whole virus, inactivated)
The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Pegcetacoplan.
Tofacitinib
Pegcetacoplan may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Pegcetacoplan.
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Pegcetacoplan.
Typhoid Vi polysaccharide vaccine
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Pegcetacoplan.
Ublituximab
The risk or severity of infection can be increased when Ublituximab is combined with Pegcetacoplan.
Varicella zoster vaccine (recombinant)
The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Pegcetacoplan.
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Pegcetacoplan.
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Pegcetacoplan.
Cladribine
Pegcetacoplan may increase the immunosuppressive activities of Cladribine.
Inebilizumab
The risk or severity of infection can be increased when Pegcetacoplan is combined with Inebilizumab.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Pegcetacoplan.
Vibrio cholerae CVD 103-HgR strain live antigen
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Pegcetacoplan.